Profile data is unavailable for this security.
About the company
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
- Revenue in USD (TTM)0.00
- Net income in USD-26.44m
- Incorporated2021
- Employees12.00
- LocationContext Therapeutics Inc2001 Market Street, Suite 3915 Unit #15PHILADELPHIA 19103United StatesUSA
- Phone+1 (267) 225-7416
- Fax+1 (302) 655-5049
- Websitehttps://www.contexttherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Voyager Therapeutics Inc | 31.32m | -126.78m | 188.48m | 172.00 | -- | 0.8556 | -- | 6.02 | -2.17 | -2.17 | 0.5358 | 3.96 | 0.0877 | -- | 2.64 | 182,069.80 | -35.50 | -1.01 | -39.95 | -1.27 | -- | -- | -404.85 | -2.34 | -- | -- | 0.00 | -- | -68.00 | -5.18 | -149.12 | -- | -14.53 | -- |
| Humacyte Inc | 1.57m | -36.97m | 194.93m | 218.00 | -- | -- | -- | 124.08 | -0.2206 | -0.2206 | 0.011 | -0.0299 | 0.0152 | -- | -- | 7,206.42 | -35.84 | -41.46 | -46.28 | -45.37 | 60.53 | -- | -2,353.22 | -8,438.13 | 0.8965 | -- | 1.10 | -- | -- | -- | -34.24 | -- | -28.00 | -- |
| CAMP4 Therapeutics Corp | 3.80m | -53.40m | 199.74m | 55.00 | -- | 3.08 | -- | 52.54 | -2.48 | -2.48 | 0.1746 | 1.25 | 0.0706 | -- | 1.81 | 69,127.27 | -99.11 | -- | -121.32 | -- | -- | -- | -1,404.47 | -- | -- | -- | 0.0013 | -- | 86.29 | -- | -5.07 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 0.00 | -47.66m | 201.90m | 15.00 | -- | 1.71 | -- | -- | -1.15 | -1.15 | 0.00 | 0.9745 | 0.00 | -- | -- | 0.00 | -113.51 | -56.32 | -131.71 | -65.21 | -- | -- | -- | -1,965.97 | -- | -- | 0.00 | -- | -100.00 | -- | -44.62 | -- | -- | -- |
| Alector Inc | 69.05m | -107.74m | 204.11m | 156.00 | -- | 3.48 | -- | 2.96 | -1.07 | -1.07 | 0.6893 | 0.5371 | 0.1622 | -- | -- | 290,117.70 | -25.31 | -19.30 | -34.27 | -23.57 | -- | -- | -156.03 | -108.92 | -- | -- | 0.1428 | -- | 3.60 | 36.50 | 8.70 | -- | -39.33 | -- |
| Arcturus Therapeutics Holdings Inc | 97.60m | -66.71m | 204.85m | 174.00 | -- | 0.8744 | -- | 2.10 | -2.46 | -2.46 | 3.60 | 8.25 | 0.2989 | -- | 5.12 | 560,919.60 | -20.43 | -19.22 | -24.18 | -24.16 | -- | -- | -68.35 | -68.95 | -- | -- | 0.00 | -- | -8.69 | 48.93 | -172.30 | -- | -4.55 | -- |
| Surrozen Inc | 3.60m | -86.91m | 209.83m | 40.00 | -- | -- | -- | 58.22 | -19.76 | -19.76 | 0.6008 | -2.74 | 0.0507 | -- | 0.4882 | 90,100.00 | -122.36 | -60.48 | -134.33 | -68.26 | -- | -- | -2,411.38 | -993.19 | -- | -- | -- | -- | -- | -- | -47.68 | -- | -55.92 | -- |
| Silence Therapeutics plc | 25.81m | -65.01m | 210.19m | 115.00 | -- | 3.06 | -- | 8.14 | -0.462 | -0.462 | 0.1831 | 0.5227 | 0.1383 | -- | 124.98 | -- | -34.83 | -39.00 | -39.01 | -48.09 | 91.20 | 55.91 | -251.86 | -203.50 | -- | -- | 0.00 | -- | 36.71 | 168.26 | 16.45 | -- | 78.99 | -- |
| Heron Therapeutics Inc | 155.10m | -13.58m | 210.87m | 122.00 | -- | 30.02 | -- | 1.36 | -0.0809 | -0.0809 | 0.9199 | 0.0812 | 0.6604 | 0.6977 | 2.09 | 1,271,287.00 | -5.78 | -50.09 | -9.22 | -70.09 | 73.92 | 56.53 | -8.75 | -136.13 | 1.78 | -- | 0.9037 | -- | 13.57 | -0.2317 | 87.72 | -- | -24.93 | -- |
| Context Therapeutics Inc | 0.00 | -26.44m | 211.32m | 12.00 | -- | 2.89 | -- | -- | -0.2835 | -0.2835 | 0.00 | 0.7964 | 0.00 | -- | -- | 0.00 | -31.94 | -44.73 | -33.64 | -57.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.52 | -- | -- | -- |
| Quantum-Si Inc | 3.18m | -116.85m | 213.46m | 143.00 | -- | 0.9076 | -- | 67.19 | -0.6589 | -0.6589 | 0.0176 | 1.09 | 0.0128 | 0.404 | 3.58 | 22,216.78 | -47.06 | -- | -50.90 | -- | 51.65 | -- | -3,677.97 | -11,135.53 | 10.59 | -- | 0.00 | -- | 182.62 | -- | -5.26 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -52.35m | 223.58m | 25.00 | -- | 6.60 | -- | -- | -1.38 | -1.38 | 0.00 | 0.6365 | 0.00 | -- | -- | 0.00 | -104.74 | -95.73 | -125.36 | -142.31 | -- | -- | -- | -- | -- | -- | 0.2271 | -- | -- | -- | -33.58 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -28.87m | 232.07m | 13.00 | -- | 12.22 | -- | -- | -1.31 | -1.31 | 0.00 | 0.7171 | 0.00 | -- | -- | 0.00 | -105.10 | -123.50 | -188.03 | -201.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.95 | -- | -- | -- |
| Neonc Technologies Holdings Inc | 59.99k | -48.88m | 232.37m | 3.00 | -- | -- | -- | 3,873.44 | -2.59 | -2.59 | 0.0032 | -0.6067 | 0.0176 | -- | -- | -- | -1,431.87 | -- | -- | -- | 33.34 | -- | -81,472.06 | -- | -- | -22.45 | -- | -- | 17.80 | -- | 20.26 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Context Therapeutics Inc's reporting currency: US Dollar USD
41.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 31 Dec 2025 | 7.42m | 8.08% |
| Avidity Partners Management LPas of 31 Dec 2025 | 5.50m | 5.99% |
| Soleus Capital Management LP (Investment Management)as of 02 Feb 2026 | 4.78m | 5.20% |
| Great Point Partners LLCas of 30 Sep 2025 | 4.68m | 5.10% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 4.00m | 4.36% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.43m | 3.74% |
| Marshall Wace LLPas of 31 Dec 2025 | 2.59m | 2.82% |
| Blackstone Alternative Asset Management LPas of 30 Sep 2025 | 2.44m | 2.66% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 1.66m | 1.81% |
| Sio Capital Management LLCas of 30 Sep 2025 | 1.34m | 1.46% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
